SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process. ...

SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial SciSparc and Clearmind’s collaboration continues to yield positive outcomes, the latest with Clearmind results for treating obesity and its related metabolic disorders TEL AVIV, Israel, Jan. ...

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...